AI Analysis
AI-generated analysis. Always verify with the original filing.
FY2025 losses stabilized near prior-year levels amid R&D cost discipline from lower headcount and expired stock options, while operating cash burn improved but liquidity remains critically constrained with ongoing negative flows expected until regulatory milestones.
Key Takeaways
1Net loss widened slightly to -$25.5M from -$25.4M, a -14.9% change driven by lower R&D headcount and reduced stock option expenses from prior forfeitures and vestings.
2Diluted EPS improved 71.4% to -$10.41 from -$36.38, reflecting moderated losses relative to stable share count.
3Revenue remained at $0.00 consistent with prior year, as clinical-stage operations generated no commercial income.
4Net cash used in operating activities improved to -$22.0M from -$36.0M, signaling better cash management amid persistent burn.
5No capital expenditures in FY2025 versus $5K prior year, preserving liquidity in a no-revenue environment.
6Management is pursuing capital options like debt or collaborations and considering expense reductions via reorganization to address going concern risks.